BioSpace News Archive

BeiGene Announces Acceptance of a Supplemental Biologics License Application in China for Tislelizumab in Microsatellite Instability-High or Mis-match Repair-Deficient Solid Tumors.

Arvinas, Inc., a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, joined state and local officials, fellow tenants, and community partners, in a groundbreaking ceremony for 101 College Street, a new 525,000-square-foot-building to be constructed as part of New Haven’s Downtown Crossing revitalization project.

Biofacturing leader Zymergen today announced the company will be participating in the upcoming Goldman Sachs Annual Global Healthcare Virtual Conference.

Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health,” the “Company” or the “Offeror”) announced today the results to date of its pending cash tender offer (the “Tender Offer”), to purchase any and all of its outstanding 7.00% Senior Secured Notes due 2024 (the “Notes”), as well as the anticipated early settlement date for the Tender Offer on June 8, 2021 (the “Early Settlement Date”).

Innovent Biologics, Inc. (“Innovent”, HKEX: 01801), together with IASO Biotherapeutics (IASO Bio), jointly announced to deliver an oral presentation on updated data from the Phase I study of IBI326 in patients with relapsed/refractory multiple myeloma (R/R MM) at the European Hematology Association (EHA) Congress,

The report highlights trends prevailing in the global market, and drivers and restraints pertaining to the market growth.

The expansion of production facilities and development of a dedicated Life Sciences Technology Center address the increased demand for bioprocessing assemblies.

PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today announced that it is providing its PhenoVue™ Cell Painting Kits to the Joint Undertaking in Morphological Profiling-Cell Painting (JUMP-CP) consortium

On behalf of those impacted by Alzheimer’s disease, the Alzheimer’s Association enthusiastically welcomes today’s historic FDA approval of aducanumab (Biogen/Eisai) for treatment of Alzheimer’s disease.

Alexion Announces FDA Approval of ULTOMIRIS ® (ravulizumab-cwvz) for Children and Adolescents with Paroxysmal Nocturnal Hemoglobinuria (PNH).